During the 8th annual Microbiome Movement Drug Development Europe, held in Barcelona (Spain), Microbiomepost conducted an exclusive interview with Satish Chandran, President and Chief Executive Officer at Prodigy Biotech, Inc.
Prodigy Biotech, an emergent player in the biotech field, capitalizes on chicken-derived immunoglobulin-Y to combat diverse diseases. In this interview Satish Chandran details the company’s innovative platform and its disease-specific targets. The forefront of their pipeline is a program aimed at treating alcoholic liver disease, spotlighting Enterococcus faecalis—a bacterial species implicated in alcoholic hepatitis—as the primary antagonist. Their pioneering candidate, PRO-AH-001, is a tailored polyclonal antibody cocktail designed to neutralize Enterococcus faecalis and its associated cytolysin toxin. The candidate has shown promising results across various pre-clinical studies, including sophisticated 3D cell cultures and animal trials.
